51results about How to "Inhibition level" patented technology

The invention discloses a novel sludge drying processing device, and belongs to the technical field of environmental protection equipment. The novel sludge drying processing device comprises a feeding machine, an air blower, an air heater, a diffuser, air flow dryers, a cyclone dryer, a cyclone separator, a dust remover, and an induced draft fan; air is heated by the air heater to a temperature higher than 100 DEG C, is delivered into the diffuser, and is mixed with dewatered sludge so as to obtain a hot air sludge flow, wherein water content of the dewatered sludge is controlled to be 80%, and the dewatered sludge is delivered into the diffuser via the feeding machine, and is smashed using the diffuser; sludge in the hot air sludge flow is dried using the air flow dryers and the cyclone dryer, dried air sludge flow is delivered into the cyclone separator so as to obtain dried sludge with a water content less than 5% via separation; hot air and dried sludge dust are delivered into the dust remover; and dried sludge dust is discharged via the bottom of the dust remover. The novel sludge drying processing device is used for processing sludge using a man-made heat source, deep dewatering is realized, thermal treatment effect is achieved, the activity of microorganisms in sludge are inhibited, and the obtained dried sludge can be taken as fertilizers, building materials, and the like.

The invention discloses a converter station near-zone short-circuit current control method and system. The method comprises the steps: building an electromagnetic transient simulation model of a voltage sourced converter (VSC) connected to a power grid near zone, and initially setting a station-level control mode of a flexible DC power transmission system; judging whether the bus short-circuit current of the VSC near zone station is greater than a preset short-circuit current threshold value under the current control mode, and obtaining a first judgment result; and when the first judgment result indicates that the first judgment result is greater than the preset short-circuit current threshold value, switching the control mode of the reactive power of the VSC near region into a constant reactive power 0Mvar. According to the invention, the reactive power control mode of VSC is adjusted, the contribution current amplitude / phase during the short-circuit fault of the VSC is changed, the near-region short-circuit current level of the converter station is suppressed by changing the vector superposition relationship between the flexible direct-current contribution current component and the alternating-current short-circuit current component, and the problem that the near-region short-circuit current of the converter station exceeds the standard after the converter station is flexiblyand directly connected into a power grid is solved.

The application discloses a vehicle-mounted video image stabilization method. The method comprises: extracting feature points in a video frame sequence; matching each two adjacent frames of feature points in the video frame sequence to obtain a set of matched feature point pairs; calculating a matrix parameter of a camera motion model; calculating a horizontal average motion vector of horizontal displacement A and a vertical average motion vector of vertical displacement; calculating a to-be-filtered horizontal motion vector according to the horizontal average motion vector and calculating a to-be-filtered vertical motion vector according to the vertical average motion vector; and carrying out motion compensation on the video frame sequence by using the a to-be-filtered horizontal motion vector and the to-be-filtered vertical motion vector. Therefore, random jittering between successive frames in a video frame sequence is compensated; horizontal and vertical movements occurring during a video shooting process are suppressed; the moving track of the video frame sequence after image stabilization becomes smooth; the vehicle-mounted video quality is improved; and the post processing of the vehicle-mounted video is realized smoothly.

A composite medicine for treating hypertension contains proportionally one or two antihypertensive medicines chosen from calcium antagon, alpha receptor blocker, beta receptor blocker, renin-angiotonin system regulator and diuretic, one Ca containing component and the farmacologically acceptable auxiliary.

The invention discloses an overlapped spectrum based low-order phase error estimation method. The method includes taking echo signals of two adjacent frequency points needing low-order phase error estimation, respectively performing distance-direction matched filtering on the echo signals, then multiplying by linear phases prior to Fourier transformation, and finally acquiring phase errors to perform compensation. According to the method, the low-order phase errors between the adjacent frequency points are estimated and then compensated, so that the purpose for inhibiting grating lobes can be achieved.

The invention discloses a universal type automatic sorting machine for multispectral imaging mixed plastics. The universal type automatic sorting machine comprises a machine frame, a speed building module, a multispectral imaging recognition module, a sorting execution module and a data collection computing control module. The speed building module is used for enabling detected plastic parts to reach the designed speed and enabling the plastic parts to obtain the enough speed when leaving the speed building module so as to build a parabolic flight path needed in the design; the multispectral imaging recognition module is arranged above the speed building module and can recognize all common plastics; the sorting execution module is used for separating out the target plastic parts by damaging the flight path of the plastic parts in the plastic flying process; the data collection computing control module is the neural center of the whole automatic sorting machine and is responsible for the cooperative work of the speed building module, the multispectral imaging recognition module and the sorting execution module, so that the operations such as accelerating, recognizing and selecting the detected plastic parts are completed; and the accuracy and efficiency are high.

The invention provides the application of carubinose in preparing medicine that can treat lung acute inflammation diseases. The molecular formula of carubinose is C6H12O6, the structure is D-carubinose. Said medicine comprises medicine acceptable shaping agent or carrying agent. The produced dosage form mainly comprises liquid dosage form, granule, tablet, gas spraying form, drop or pill. The invention can reduce the lung tissue TNF-alpha level of mice ALT model induced by LPS, release neutral granulocyte wettability in lung tissue, inhibit capillary blood permeability, decrease protein exudation and lung water content, reduce MPO level in BALF supernatant and improve pathologic change for lung tissue inflammation. The invention discloses the functions of anti-inflammation, anti-oxidation and pneumochysis reduction of carubinose.

The invention discloses a biological preparation capable of improving eye vitality comprehensively, bringing fresh and cool feelings to users and making skin firm within a short time, and further discloses a preparation method of the biological preparation. Main ingredients of the biological preparation include various functional active peptides such as recombinant human epidermal growth factors (rhEGF), and various medicinal herb extracts; therefore, the biological preparation improves skin cell vitality, strengthens expressions of collagen and elastin, promotes skin microcirculation, and regulates periocular neurotransmitter to achieve comprehensive regulation and prevention of problems of eye skins. As combined with the conventional nursing method, the biological preparation also has functions of removing free radicals, suppressing inflammatory factor level, promoting blood circulation to remove blood stasis, stimulating the circulation of the blood and relaxing muscles and joints and the like, and accordingly improves eye health comprehensively.

The invention discloses a lactobacillus reuteri composition capable of relieving rheumatoid arthritis, and belongs to the technical field of food microorganisms. The concentrated biological preparation is prepared by activating lactobacillus reuteri CCFM8631 and lactobacillus reuteri CCFM14, performing enlarge cultivation, performing centrifugation, and performing re-suspension in a 30% sucrose solution; and the numbers of viable bacteria of the lactobacillus reuteri CCFM8631 and CCFM14 obtained by a plate count process are both greater than 10<10> CFU / mL. The lactobacillus reuteri composition provided by the invention can significantly alleviate rheumatoid arthritis induced by type II collagen, relieve joint redness and swelling symptoms, inhibit the level of antibodies resisting againstthe type II collagen, reduce the content of proinflammatory cytokines and anti-inflammatory cytokines in serum, reduce the levels of Th1 and Th2 cell-related effect characteristic factors, improve anintestinal function, and has broad market application prospects.

The invention relates to application of oleanolic acid in preparation of drugs for treatment autoimmune diseases, and belongs to the technical field of biomedicine. The oleanolic acid can inhibit thefunction of the transcription factor ROR[gamma]t, inhibit the differentiation of Th17 cells, and inhibit the transcriptional expression of the target genes IL-17A and IL-17F of ROR[gamma]t at the RNAlevel, and inhibit IL-17A cytokines. The secretion inhibits the level of anti-dsDNA antibodies in the serum; the oleanolic acid of the present invention has an obvious Th17 cell activity inhibitory function, and provides a lead structure for the development of new drugs for the treatment of autoimmune diseases.

The invention discloses application of a thiadiazole compound in the preparation of a medicament for preventing and treating bacterial seedling damping-off of rice. A preparation prepared by using the thiadiazole compound as a main effective component is capable of effectively inhibiting the level of tropolone produced by B. plantarii, and therefore, the bacterial seedling damping-off of the rice can be prevented and treated. The medicament provided by the invention can be utilized for simply and feasibly preventing and treating the bacterial seedling damping-off of rice, is low in cost and has good prevention and treatment effects.

The invention relates to a retroviral recombinant capable of efficiently expressing siRNA targeting the ATP binding region of BCRP / ABCG2 gene, which belongs to the field of genetic engineering. Retroviral recombinants are recombined with retroviral RNAi expression system and oligonucleotide fragments, and are packaged by viral packaging cells. The invention is mainly applied to the drug resistance reversal of the breast cancer resistance protein.

The invention relates to a method for analyzing a linear frequency modulation signal. The method comprises the following steps: carrying out Wignard WVD conversion on the linear frequency modulation signal to obtain a first signal; processing the first signal by using a spatial apodization SVA algorithm to obtain a second signal; performing time-frequency matrix rearrangement on the second signalto obtain a third signal; performing short-time Fourier transform (STFT) on the linear frequency modulation signal to obtain a fourth signal; and performing an AdammaHadamard product on the third signal and the fourth signal. According to the invention, the obtained time-frequency distribution can effectively reduce the sidelobe level and eliminate the phenomena of cross terms and spectrum aliasing at the same time.

The invention discloses novel application of radiation-resistant peptide proteins and provides application of radiation-resistant peptide proteins in preparation of products for inhibiting liver injury diseases. The amino acid sequence of the radiation-resistant peptide proteins refers to a sequence 2 in a sequence table. The experiment proves that the radiation-resistant peptide proteins can inhibit the liver injury and can be used for preparing medicines with the effect of inhibiting the liver injury.

The present invention provides a use of a HIF-2alpha inhibitor in preparation of drugs for preventing and treating acute high-altitude reaction. The HIF-2alpha inhibitor comprises HIF-2alpha-I2 and / orPT2385; the use according to the invention fully investigates molecular mechanisms and key molecular events and processes of acute high-altitude reaction and hypoxia stress, and a series of experiments shows that HIF-2alpha-I2 and PT2385 both can significantly improve the malignant degree and symptoms including slowing shortness of breath, emotional upset, and high heart rate of acute high-altitude reaction, as well as alleviate the acute hypoxic stress response, so as to achieve the purpose of effectively preventing acute hypoxia. The use has good safety, little side effects and other advantages, and has a good application prospect.

The invention relates to the technical field of weight reduction and lipid reduction, in particular to an application of a melatonin composition in preparation of a weight-reducing and lipid-loweringdrug, the melatonin composition comprises melatonin and EGCG, and the mass ratio of the melatonin to the EGCG is (2-6): (30-45). According to the invention, the melatonin is combined with the EGCG foruse for the first time; the melatonin composition can reduce the body weight and abdominal fat weight of a mouse suffering from type 2 diabetes; the expression of fatty acid synthetase protein in abdominal fat of mice with type 2 diabetes mellitus and the expression of fatty acid synthetase protein in livers can be obviously inhibited; the melatonin composition can achieve the effects of reducingweight gain or losing weight and lowering lipid by inhibiting fat synthesis and reducing fat accumulation, stachyose is accidentally added, the quinonylation protein level can be remarkably inhibited, and the activity of EGCG can be improved.

The invention relates to a pure traditional Chinese medical compound capsule of climbing entada seed for reducing blood sugar, prepared from raw medicinal materials: climbing entada seed, safflower, common fennel, celery seed, myrobalan and strawflower and assistant materials: starch, microcrystalline cellulose and magnesium stearate. Proved by a pharmacodynamic test, the compound capsule has the functions of regulating blood fat and reducing the blood sugar, has the advantages of high safety, good stability and no obvious toxic or side effects and medicine resistant property, is used for treating type I diabetes and type II diabetes and is also used as a preventive medicament for reducing the blood sugar for long-term use.

The invention relates to a pharmaceutical composition for preventing and curing atherosclerosis. The pharmaceutical composition is prepared from an effective constituent and a pharmaceutically accepted ingredient, and is characterized in that the effective constituent is prepared from the following raw materials with the following weight ratio: geniposide to notoginsenoside R1 in a ratio of (1 to2) to (2 to 1). The pharmaceutical composition has the effects of lowering blood lipid level, inhibiting inflammation and reducing atherosclerotic plaques, and has a remarkable effect on improvement of the atherosclerosis.

The invention discloses a biomarker LINC01549 related to hepatocellular carcinoma and application thereof. The invention finds that expression of the LINC01549 is up-regulated in a patient suffering from the hepatocellular carcinoma for the first time, and after further verification through a large sample, a result shows that the LINC01549 as a detection substance has a relatively high positive detection rate; experiments further prove that the LINC01549 is related to proliferation, migration and invasion of hepatoma carcinoma cells, which indicates that the LINC01549 can be used as a medicinetarget for clinical treatment of the hepatocellular carcinoma.

The invention discloses an application of erythritol in preparation of a medicine for treating non-alcoholic fatty liver. Pharmacological experiments show that the erythritol has a good treatment effect on a non-alcoholic fatty liver mouse model and a hepatocyte lipid accumulation model. Experimental results prove that the erythritol can effectively reduce the lipid content in hepatocytes by regulating expression of acetyl-coenzyme A carboxylase (ACC) and cholesterol regulatory element binding protein 1c (SREBP-1c) in hepatocytes; In mice with non-alcoholic fatty liver, the erythritol can significantly reduce lipid accumulation in the liver and can significantly inhibit the levels of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase. In a word, the erythritol can play a role in regulating the blood fat by inhibiting the expression of SREBP-1 and ACC.

The invention discloses a method for preparing the recombinant protein swHO1, extracting the total RNA of the liver tissue of rice field eel, and cloning the coding gene of rice field eel heme oxidase 1 into an expression vector through reverse transcription and PCR amplification to obtain the recombinant expression vector pET ‑HO1; transforming the recombinant expression vector pET‑HO1 into Escherichia coli BL21 (DE3) cells for expression and purification to obtain the recombinant protein swHO1. The application of a recombinant protein swHO1 in the regulation of oxidative stress induced by pathogenic bacteria and the expression regulation of immune-related genes in rice field eel. The invention constructs the prokaryotic expression vector of the eel heme oxidase 1 gene, induces the expression, and obtains the purified recombinant protein swHO1 by affinity chromatography. The rice field eel heme oxidase 1 prepared by the invention has the functions of improving the antioxidant capacity in the serum tissue treated with pathogenic bacteria and improving the expression of liver immune-related genes.

The invention discloses an application of tanshinone IIA sulfonate sodium in preparation of a medicine. Blood is taken from the right ventricle 12 hours and 3 days after myocardial infarction, and the myocardial enzyme lactic dehydrogenase is detected. After the tanshinone IIA sulfonate sodium is used, LDH level begins to decrease after myocardial infarction for 12 hours, myocardial cell necrosis or injury begins to decrease, and significant difference is achieved in 3 days, so that the tanshinone IIA sulfonate sodium can significantly inhibit LDH level in plasma, especially LDH increase caused by myocardial cell necrosis or injury. Therefore, the tanshinone IIA sulfonate sodium can effectively inhibit the LDH level in a mouse body, and can be used for preparing antiepileptic drugs.

The invention discloses the application of saponin VII in the preparation of MSN protein inhibitor. Through series of experiments, it is proved that the saponin VII of papaya has anti-multiple myeloma activity. And saponin VII of pagoda plant exerted anti-multiple myeloma activity by directly inhibiting the protein level of MSN and targeting the side population cells of multiple myeloma stem cell-like cells. Papaya saponin VII can be used as an inhibitor of MSN protein to treat diseases caused by increased expression of MSN protein, such as multiple myeloma, and is expected to be developed as a new type of antitumor drug.

The invention discloses a biological preparation capable of improving eye vitality comprehensively, bringing fresh and cool feelings to users and making skin firm within a short time, and further discloses a preparation method of the biological preparation. Main ingredients of the biological preparation include various functional active peptides such as recombinant human epidermal growth factors (rhEGF), and various medicinal herb extracts; therefore, the biological preparation improves skin cell vitality, strengthens expressions of collagen and elastin, promotes skin microcirculation, and regulates periocular neurotransmitter to achieve comprehensive regulation and prevention of problems of eye skins. As combined with the conventional nursing method, the biological preparation also has functions of removing free radicals, suppressing inflammatory factor level, promoting blood circulation to remove blood stasis, stimulating the circulation of the blood and relaxing muscles and joints and the like, and accordingly improves eye health comprehensively.

The invention discloses an application of a Guanxin salvia miltiorrhiza compound preparation in preparing a medicine for improving ventricular remodeling. The Guanxin salvia miltiorrhiza compound preparation is composed of 200 g of salvia miltiorrhiza, 200 g of pseudo-ginseng and 1.75 mL of dalbergiae odoriferae oil. The application comprises that for ventricular remodeling generated after acute ST-segment elevation myocardial infarction (STEMI) coronary artery recanalization, the Guanxin salvia miltiorrhiza compound preparation can effectively reduce levels of aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and creatine kinase isoenzyme (CKMB) after STEMI coronary artery recanalization, improves systolic functions, reduces the area of myocardial fibrosis, and plays a major role in effectively improving ventricular remodeling.

The invention relates to the technical field of medicines, in particular to an application of nosiheptide to preparation of a periodontitis treatment medicine. The application proves that the nosiheptide has a treatment effect on a rat periodontitis model, can effectively improve the bone volume fraction, reduces the separation degree of bone trabecula, promotes osteogenesis, increases bone mass, inhibits inflammatory factors NF-K beta and TNF-alpha, inhibits the inflammatory cell level in periodontium, promotes fibroblast generation, promotes periodontium inflammation repair, facilitates periodontitis treatment, and does not have the side effects of enabling users to generate anorexia and influencing growth. The experimental result has clinical significance, and a new scheme is provided for clinical treatment of periodontitis.

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.